Details

Autor(en) / Beteiligte

• Cioli, Donato
• Pica-Mattoccia, Livia
• Basso, Annalisa
• Guidi, Alessandra

Titel

Schistosomiasis control: praziquantel forever?

Ist Teil von

• Molecular and biochemical parasitology, 2014-06, Vol.195 (1), p.23-29

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Potential attack points (red arrows) for the control of Schistosoma mansoni. •No schistosomiasis vaccine exists and the intermediate host is difficult to combat.•The only available drug is praziquantel.•Praziquantel is safe, effective, economical and convenient.•Repeated mass treatment of millions of people may induce resistance.•Alternative compounds have been tested, but none so far is completely satisfactory. Since no vaccine exists against schistosomiasis and the molluscs acting as intermediate hosts are not easy to attack, chemotherapy is the main approach for schistosomiasis control. Praziquantel is currently the only available antischistosomal drug and it is distributed mainly through mass administration programs to millions of people every year. A number of positive features make praziquantel an excellent drug, especially with regard to safety, efficacy, cost and ease of distribution. A major flaw is its lack of efficacy against the immature stages of the parasite. In view of its massive and repeated use on large numbers of individuals, the development of drug resistance is a much feared possibility. The mechanism of action of praziquantel is still unclear, a fact that does not favor the development of derivatives or alternatives. A large number of compounds have been tested as potential antischistosomal agents. Some of them are promising, but none so far represents a suitable substitute or adjunct to praziquantel. The research of new antischistosomal compounds is an imperative and urgent matter.